Clinical Trial Update: Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of ibrutinib and rituximab in treatment-naïve follicular lymphoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Follicular Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2026-03-17